1. Medtech Insight
  2. >>Business
  3. >>Financing

Merck, Amgen Invest In Medical Video Game Developer Akili

 
• By Lubna Ahmed

Akili Interactive Labs Inc., a digital medicine company, has secured an additional $11.9m funding via series B financing with backing from Merck KGaA and Amgen Inc.

Akili Interactive Labs Inc. has expanded its series B financing with an additional $11.9m from new investors Merck Ventures BV, Amsterdam, the Netherlands, a subsidiary of Merck KGAA , and Amgen Ventures, the venture arm of Amgen Inc.

Earlier this year, Akili raised $30.5m from investors including JAZZ Venture Partners, Canepa Advanced Healthcare Fund and PureTech totaling the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

Tempus AI Buys Paige. AI For $81.25M To Help Build Largest Oncology Foundation Model

 
• By Marion Webb

Tempus expects its $81.25m acquisition of Paige AI to accelerate building the largest oncology foundation model. With its third deal this year, Tempus expands capabilities across genomics, pathology, and clinical trials.

Terumo’s $1.5Bn Buyout Of OrganOx Vaults Company Into Organ Preservation Market

 
• By Marion Webb

Terumo will acquire OrganOx for about $1.5bn, adding the only FDA-cleared liver normothermic perfusion device to its portfolio. Analysts don’t expect the buyout to have a significant impact on competition, but the deal marks a strategic shift for Terumo into transplant medicine.

SetPoint Medical Raises $140M: Pipeline Expansion And Multiple Sclerosis Clinical Trial On Horizon

 
• By Natasha Barrow

SetPoint Medical secured US FDA approval for its vagus nerve neuromodulation device to treat RA. Now, the start-up is tasked with convincing both rheumatologist and surgeons to adopt its technology over or alongside biologic drugs. CEO Murthy Simhambhatla talks exit strategy plans.

Medtronic Posts Solid First-Quarter, Adds Board Members As Elliott Takes Stake

 
• By Marion Webb

Medtronic beat first-quarter revenue and EPS estimates, raised guidance, and added two board members and special committees as Elliott takes a stake.

More from Business

SetPoint Medical Raises $140M: Pipeline Expansion And Multiple Sclerosis Clinical Trial On Horizon

 
• By Natasha Barrow

SetPoint Medical secured US FDA approval for its vagus nerve neuromodulation device to treat RA. Now, the start-up is tasked with convincing both rheumatologist and surgeons to adopt its technology over or alongside biologic drugs. CEO Murthy Simhambhatla talks exit strategy plans.

German Health Researchers Prep for Possible Disruptions to PubMed, ClinicalTrials.gov

 
• By Elizabeth Orr and Francesca Bruce

IQWiG, Germany’s health technology assessment body, is making contingency plans in case key US resources it relies on for information retrieval, when conducting benefit assessments of new medicines, become unavailable.

Alcon Drops Revenue Projections After Soft Q2 Sales

 
• By Elizabeth Orr

The vision company expects total annual revenues of $10.3bn-$10.4bn, marking a slower growth rate than earlier forecasts. However, management remains optimistic that overall trends, as well as recent purchases like STAAR and LumiThera, represent a significant market opportunity.